U.S. Markets open in 7 hrs 15 mins
  • S&P Futures

    3,787.00
    +24.75 (+0.66%)
     
  • Dow Futures

    30,866.00
    +146.00 (+0.48%)
     
  • Nasdaq Futures

    12,914.00
    +111.75 (+0.87%)
     
  • Russell 2000 Futures

    2,145.80
    +25.00 (+1.18%)
     
  • Crude Oil

    52.41
    +0.05 (+0.10%)
     
  • Gold

    1,838.70
    +8.80 (+0.48%)
     
  • Silver

    25.20
    +0.34 (+1.36%)
     
  • EUR/USD

    1.2101
    +0.0018 (+0.1452%)
     
  • 10-Yr Bond

    1.0970
    0.0000 (0.00%)
     
  • Vix

    24.34
    +1.09 (+4.69%)
     
  • GBP/USD

    1.3600
    +0.0014 (+0.1020%)
     
  • USD/JPY

    104.0540
    +0.3670 (+0.3540%)
     
  • BTC-USD

    36,618.71
    +176.98 (+0.49%)
     
  • CMC Crypto 200

    719.76
    -15.38 (-2.09%)
     
  • FTSE 100

    6,720.65
    -15.06 (-0.22%)
     
  • Nikkei 225

    28,633.46
    +391.25 (+1.39%)
     

Tmunity to Present at the 39th Annual J.P. Morgan Healthcare Conference

·2 min read

​Tmunity Therapeutics, Inc., a private clinical-stage biotherapeutics company focused on saving and improving lives by delivering the full potential of next-generation T cell immunotherapy, today announced that President and CEO, Usman "Oz" Azam, will present at the 39th Annual J.P. Morgan Healthcare Conference on Tuesday, January 12, 2021 at 3:10 pm ET.

A live webcast of the presentation will be available on the "Events and Presentations" page of the Tmunity website at https://www.tmunity.com/events. Tmunity will maintain an archived replay of the webcast on the website for 30 days after the conference.

About Tmunity Therapeutics

​Tmunity is a private, clinical-stage biotherapeutics company, focused on saving and improving lives by delivering the full potential of next-generation T-cell immunotherapy to patients with devastating diseases. Integrating a foundational collaboration with the University of Pennsylvania (Penn), with groundbreaking scientific, clinical and manufacturing expertise, and the demonstrated track record of its founders (Carl June, MD; Bruce Levine, PhD; Yangbing Zhao, MD, PhD; Jim Riley, PhD; and Anne Chew, PhD), Tmunity represents a new center of gravity in translational T-cell medicine. Through Penn, the Parker Institute for Cancer Immunotherapy and other collaborations, Tmunity is developing a diversified portfolio of novel treatments that exhibit best-in-class control over T-cell activation and direction in the body, with a focus in cancer and two programs currently in clinic development.

With headquarters in Philadelphia, Tmunity utilizes laboratories and production facilities at Penn, and its own dedicated cGMP manufacturing facility in East Norriton, PA, to pursue process improvement and production scale-up in support of clinical development of its T-cell therapies. For more information, visit www.tmunity.com and connect with us on social media at @TmunityTx and LinkedIn.

View source version on businesswire.com: https://www.businesswire.com/news/home/20210105005681/en/

Contacts

Julie Seidel
Stern Investor Relations
Julie.Seidel@sternir.com
212-362-1200